<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465803</url>
  </required_header>
  <id_info>
    <org_study_id>C-06-21</org_study_id>
    <nct_id>NCT00465803</nct_id>
  </id_info>
  <brief_title>A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension</brief_title>
  <official_title>Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess patient compliance with DuoTrav versus concomitant
      administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>12 months</time_frame>
    <description>Patient compliance will be measured with a dosing aid that records time and date of study drug administration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>DuoTrav</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travatan/Timolol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004%/timolol 0.5% ophthalmic solution</intervention_name>
    <description>One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid</description>
    <arm_group_label>DuoTrav</arm_group_label>
    <other_name>DuoTrav</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost ophthalmic solution, 0.004%</intervention_name>
    <description>One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid</description>
    <arm_group_label>Travatan/Timolol</arm_group_label>
    <other_name>TRAVATAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol maleate ophthalmic solution, 0.5%</intervention_name>
    <description>One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid</description>
    <arm_group_label>Travatan/Timolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with open-angle glaucoma or ocular hypertension;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Visual acuity worse than 0.60;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Landry</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2007</study_first_posted>
  <disposition_first_submitted>July 22, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 22, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 24, 2014</disposition_first_posted>
  <last_update_submitted>July 22, 2014</last_update_submitted>
  <last_update_submitted_qc>July 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-angle glaucoma or ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

